← Back to Search

Cholinesterase Inhibitor

Pyridostigmine Bromide 60 Milligrams (mg) for Hoarseness

Phase 4
Waitlist Available
Led By Benjamin Rubinstein, MD
Research Sponsored by Eastern Virginia Medical School
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes
Awards & highlights

Summary

This trial tests if pyridostigmine can improve voice quality in patients with spasmodic dysphonia who have a breathy voice after their usual treatment. The medication helps muscles work better, which might enhance their voice.

Eligible Conditions
  • Hoarseness
  • Spastic Dysphonia
  • Spasmodic Dysphonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adapted Borg Scale Pre- and Post-Pyridostigmine (Mestinon)
CAPE-V Pre- and Post-Pyridostigmine (Mestinon)
Glottal Function Index Pre- and Post-Pyridostigmine (Mestinon)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pyridostigmine (Mestinon)Experimental Treatment1 Intervention
Pyridostigmine (Mestinon) will be assigned to patients in this arm.

Find a Location

Who is running the clinical trial?

Eastern Virginia Medical SchoolLead Sponsor
72 Previous Clinical Trials
15,709 Total Patients Enrolled
Benjamin Rubinstein, MDPrincipal InvestigatorEastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery
1 Previous Clinical Trials
40 Total Patients Enrolled
~2 spots leftby Sep 2025